Tavaborole (formerly known as AN-2690; AN2690; trade name Kerydin) is a topical antifungal medication approved by the US FDA in July 2014 for the treatment of onychomycosis, which is a fungal infection of the nail and nail bed. Tavaborole began its Phase 3 trials in December 2010 and was approved in July 2014. Tavaborole inhibits an essential fungal enzyme, Leucyl-tRNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. No treatment-related systemic side effects were observed in any of its clinical trials.